Literature DB >> 26443810

Oxidative Stress and Response to Thymidylate Synthase-Targeted Antimetabolites.

Ufuk Ozer1, Karen W Barbour1, Sarah A Clinton1, Franklin G Berger2.   

Abstract

Thymidylate synthase (TYMS; EC 2.1.1.15) catalyzes the reductive methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) by N(5),N(10)-methyhlenetetrahydrofolate, forming dTMP for the maintenance of DNA replication and repair. Inhibitors of TYMS have been widely used in the treatment of neoplastic disease. A number of fluoropyrimidine and folate analogs have been developed that lead to inhibition of the enzyme, resulting in dTMP deficiency and cell death. In the current study, we have examined the role of oxidative stress in response to TYMS inhibitors. We observed that intracellular reactive oxygen species (ROS) concentrations are induced by these inhibitors and promote apoptosis. Activation of the enzyme NADPH oxidase (NOX), which catalyzes one-electron reduction of O2 to generate superoxide (O2 (●-)), is a significant source of increased ROS levels in drug-treated cells. However, gene expression profiling revealed a number of other redox-related genes that may contribute to ROS generation. TYMS inhibitors also induce a protective response, including activation of the transcription factor nuclear factor E2-related factor 2 (NRF2), a critical mediator of defense against oxidative and electrophilic stress. Our results show that exposure to TYMS inhibitors induces oxidative stress that leads to cell death, while simultaneously generating a protective response that may underlie resistance against such death.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26443810      PMCID: PMC4658596          DOI: 10.1124/mol.115.099614

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  36 in total

1.  Thymidylate synthase as a chemotherapeutic drug target: where are we after fifty years?

Authors:  Franklin G Berger; Sondra H Berger
Journal:  Cancer Biol Ther       Date:  2006-09-13       Impact factor: 4.742

Review 2.  Folate-based thymidylate synthase inhibitors in cancer chemotherapy.

Authors:  Y Takemura; A L Jackman
Journal:  Anticancer Drugs       Date:  1997-01       Impact factor: 2.248

Review 3.  Chemotherapy of colorectal cancer: history and new themes.

Authors:  J R Bertino
Journal:  Semin Oncol       Date:  1997-10       Impact factor: 4.929

4.  Comparative pharmacology of chemically distinct NADPH oxidase inhibitors.

Authors:  S Wind; K Beuerlein; T Eucker; H Müller; P Scheurer; M E Armitage; H Ho; H H H W Schmidt; K Wingler
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

5.  Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2.

Authors:  Xiao-Jun Wang; Zheng Sun; Nicole F Villeneuve; Shirley Zhang; Fei Zhao; Yanjie Li; Weimin Chen; Xiaofang Yi; Wenxin Zheng; Georg T Wondrak; Pak Kin Wong; Donna D Zhang
Journal:  Carcinogenesis       Date:  2008-04-15       Impact factor: 4.944

6.  5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress.

Authors:  Monica Lamberti; Stefania Porto; Monica Marra; Silvia Zappavigna; Anna Grimaldi; Daniela Feola; Delia Pesce; Silvio Naviglio; Annamaria Spina; Nicola Sannolo; Michele Caraglia
Journal:  J Exp Clin Cancer Res       Date:  2012-07-19

Review 7.  The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer.

Authors:  Emilia Kansanen; Suvi M Kuosmanen; Hanna Leinonen; Anna-Liisa Levonen
Journal:  Redox Biol       Date:  2013-01-18       Impact factor: 11.799

8.  Identification of NCF2/p67phox as a novel p53 target gene.

Authors:  Dafne Italiano; Anna Maria Lena; Gerry Melino; Eleonora Candi
Journal:  Cell Cycle       Date:  2012-11-27       Impact factor: 4.534

Review 9.  Cytoprotection "gone astray": Nrf2 and its role in cancer.

Authors:  Claudia Geismann; Alexander Arlt; Susanne Sebens; Heiner Schäfer
Journal:  Onco Targets Ther       Date:  2014-08-26       Impact factor: 4.147

Review 10.  The Nrf2 regulatory network provides an interface between redox and intermediary metabolism.

Authors:  John D Hayes; Albena T Dinkova-Kostova
Journal:  Trends Biochem Sci       Date:  2014-03-16       Impact factor: 13.807

View more
  6 in total

Review 1.  The major contribution of the DNA damage-triggered reactive oxygen species production to cell death: implications for antimicrobial and cancer therapy.

Authors:  Ivan Matic
Journal:  Curr Genet       Date:  2017-11-27       Impact factor: 3.886

2.  Toxicity, recovery, and resilience in a 3D dopaminergic neuronal in vitro model exposed to rotenone.

Authors:  Georgina Harris; Melanie Eschment; Sebastian Perez Orozco; J Michael McCaffery; Richard Maclennan; Daniel Severin; Marcel Leist; Andre Kleensang; David Pamies; Alexandra Maertens; Helena T Hogberg; Dana Freeman; Alfredo Kirkwood; Thomas Hartung; Lena Smirnova
Journal:  Arch Toxicol       Date:  2018-06-28       Impact factor: 5.153

3.  Bruceine D Identified as a Drug Candidate against Breast Cancer by a Novel Drug Selection Pipeline and Cell Viability Assay.

Authors:  Claudia Cipriani; Maria Pires Pacheco; Ali Kishk; Maryem Wachich; Daniel Abankwa; Elisabeth Schaffner-Reckinger; Thomas Sauter
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-31

4.  miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways.

Authors:  Guoshu Bi; Jiaqi Liang; Mengnan Zhao; Huan Zhang; Xing Jin; Tao Lu; Yuansheng Zheng; Yunyi Bian; Zhencong Chen; Yiwei Huang; Valeria Besskaya; Cheng Zhan; Qun Wang; Lijie Tan
Journal:  Mol Ther Nucleic Acids       Date:  2022-03-28       Impact factor: 8.886

5.  The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase.

Authors:  Xinyuan Ding; Yuting Gu; Min Jin; Xin Guo; Sudong Xue; Caihong Tan; Jiefang Huang; Wanlin Yang; Mingxing Xue; Qianjun Zhou; Wenjuan Wang; Yanyun Zhang
Journal:  Theranostics       Date:  2020-05-15       Impact factor: 11.556

6.  Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.

Authors:  Chia-Sing Lu; Ching-Wen Lin; Ya-Hsuan Chang; Hsuan-Yu Chen; Wei-Chia Chung; Wei-Yun Lai; Chao-Chi Ho; Tong-Hong Wang; Chi-Yuan Chen; Chen-Lin Yeh; Sean Wu; Shu-Ping Wang; Pan-Chyr Yang
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.